Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The nature of the side chain in RU 58841 derivatives greatly affects its AR affinity, with the N-(iodopropenyl) derivative 13 showing the highest AR binding affinity, suggesting its potential for developing high-affinity radioiodinated AR radioligands.

Agomelatine may help reduce benign prostatic hyperplasia by blocking certain inflammatory pathways.

Treatment with a hormone agonist can reduce excess male hormones in postmenopausal women without surgery.

Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.

14,15-EET may help reduce poststroke pain by affecting certain brain proteins.

Combination therapy with fesoterodine and doxazosin improves bladder function and delays BPH progression.

New nonsteroidal molecules can potentially increase dihydrotestosterone in neurons by blocking certain enzymes, without affecting prostate and seminal vesicle weight.

Alpha-blockers are the most effective and widely used treatment for lower urinary tract symptoms, with minimal side effects.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

Activating androgen receptors in muscle can increase muscle mass and reduce fat.

Combining dutasteride or finasteride with an α1 blocker is more effective for managing BPH than using either alone.

SARMs may offer benefits by boosting muscle effects without unwanted side effects.

Drugs targeting the Androgen Receptor are effective for treating prostate cancer and other androgen-related conditions.

Scientists created iodinated arylhydantoins and arylthiohydantoins that could potentially be used for imaging prostate cancer. Some versions with specific side-chains showed high potential for this use.

OXTR agonists may promote hair growth and be effective for treating hair loss.

Alpha1-blockers effectively improve urinary symptoms in BPH, with alfuzosin and tamsulosin having fewer side effects.

ADT for prostate cancer may harm the heart, but GnRH antagonists might be safer.

Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.

New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.

New steroids were effective in blocking male hormone receptors in hamster prostates.

5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.

A new treatment for hair loss shows promise with fewer side effects.

Combining a GnRH agonist with a low-dose oral contraceptive is more effective and safer for treating hirsutism than using either alone.

Testosterone reduces knee movement, while flutamide and finasteride increase it.

A new topical treatment for hair loss shows strong hair growth effects with low toxicity.

Certain drugs can reduce bladder muscle contractions, potentially helping treat bladder diseases.

The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.

New compounds with carborane showed anti-androgen effects similar to flutamide.

Antiandrogens affect androgen-dependent body functions and are used for various medical conditions, with some risks like fetus feminization, but new forms like 17α-propylmesterolone show promise for acne without systemic effects.

Scoring systems help doctors assess and treat skin diseases effectively.